TRDA
Entrada Therapeutics, Inc.$6.48+0.17 (+2.69%)Prev Close$6.31·MCap$274.5M·P/E—·Vol115.9K·Yield—
▲
Buys (12M)
1
$29.3K
▼
Sells (12M)
14
$4.16M
◆
Net Activity
Net Seller
$4.13M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Entrada Therapeutics, Inc. (TRDA) has been dominated by selling, with 1 insider purchase totaling $29.3K and 14 insider sales totaling $4.16M. The most recent insider transaction was by Zeiher Bernhardt G (director), who purchased $29.3K worth of shares on May 21, 2026. Entrada Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $274.5M.
TRDA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | Zeiher Bernhardt G | director | Buy | 5,000 | $5.86 | $29.3K | 5,000 |
| May 4, 2026 | Sethuraman Natarajan | officer: President, Research & Develop. | Sell | 25,907 | $15.39 | $398.8K | 216,317 |
| May 4, 2026 | Dowden Nathan J | officer: President & COO | Sell | 15,000 | $15.33 | $230.0K | 198,588 |
| Apr 2, 2026 | WENTWORTH KORY JAMES | officer: Chief Financial Officer | Sell | 2,500 | $12.95 | $32.4K | 119,010 |
| Mar 11, 2026 | Dowden Nathan J | officer: President & COO | Sell | 15,010 | $13.04 | $195.8K | 210,482 |
| Mar 11, 2026 | WENTWORTH KORY JAMES | officer: Chief Financial Officer | Sell | 16,477 | $13.01 | $214.4K | 132,898 |
| Mar 6, 2026 | WENTWORTH KORY JAMES | officer: Chief Financial Officer | Sell | 7,988 | $12.25 | $97.9K | 137,987 |
| Nov 21, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 8,910 | $9.98 | $88.9K | 0 |
| Nov 14, 2025 | PARMAR KUSH | Director | Sell | 200,000 | $8.80 | $1.76M0.5% OS | 0 |
| Sep 2, 2025 | Doshi Dipal | CEO | Sell | 8,723 | $5.43 | $47.4K | 0 |
| Sep 2, 2025 | Dowden Nathan J | President & COO | Sell | 1,746 | $5.43 | $9.5K | 0 |
| Sep 2, 2025 | Sethuraman Natarajan | President, Research & Develop. | Sell | 1,760 | $5.43 | $9.6K | 0 |
| Sep 2, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 1,734 | $5.43 | $9.4K | 0 |
| Jul 9, 2025 | PARMAR KUSH | Director | Sell | 27,000 | $7.50 | $202.6K | 0 |
| Jun 27, 2025 | PARMAR KUSH | Director | Sell | 125,000 | $6.93 | $866.6K | 0 |
| Mar 17, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 1,784 | $10.67 | $19.0K | 0 |
| Mar 1, 2025 | Doshi Dipal | CEO | Sell | 17,566 | $11.68 | $205.1K | 0 |
| Mar 1, 2025 | Dowden Nathan J | President & COO | Sell | 5,144 | $11.68 | $60.1K | 0 |
| Mar 1, 2025 | Sethuraman Natarajan | President, Research & Develop. | Sell | 6,138 | $11.68 | $71.7K | 0 |
| Mar 1, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 4,929 | $11.68 | $57.6K | 0 |
| Dec 12, 2024 | MPM BIOVENTURES 2018, L.P. | Sell | 44,722 | $20.51 | $917.1K | 4,402,849 | |
| Dec 3, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 15,891 | $20.18 | $320.6K | 160,788 |
| Dec 3, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 6,000 | $19.99 | $119.9K | 73,849 |
| Nov 13, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 4,109 | $20.03 | $82.3K | 163,588 |
| Nov 13, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 8,637 | $19.98 | $172.6K | 73,849 |
| Nov 6, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 18,219 | $18.62 | $339.3K | 182,467 |
| Oct 18, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 600 | $18.00 | $10.8K | 183,216 |
| Sep 30, 2024 | Dowden Nathan J | President & COO | Sell | 847 | $16.00 | $13.6K | 125,149 |
| Sep 10, 2024 | Dowden Nathan J | President & COO | Sell | 2,303 | $15.09 | $34.8K | 127,900 |
| Sep 10, 2024 | Sethuraman Natarajan | Chief Scientific Officer | Sell | 3,242 | $15.12 | $49.0K | 186,458 |
| Sep 10, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 3,195 | $14.97 | $47.8K | 76,486 |
| Aug 20, 2024 | Dowden Nathan J | President & COO | Sell | 27,097 | $16.27 | $440.8K | 130,609 |
| Jul 16, 2024 | Doshi Dipal | CEO | Sell | 1,900 | $17.84 | $33.9K | 336,075 |
| Jul 16, 2024 | Sethuraman Natarajan | Chief Scientific Officer | Sell | 1,238 | $18.00 | $22.3K | 189,452 |
| Jul 10, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 1,758 | $14.95 | $26.3K | 81,412 |
| Jun 26, 2024 | BAKER BROS. ADVISORS LP | Buy | 3,367,003 | $14.85 | $50.00M8.8% OS | 3,081,303 | |
| Jun 14, 2024 | Doshi Dipal | CEO | Sell | 1,000 | $16.17 | $16.2K | 336,375 |
| May 20, 2024 | Doshi Dipal | CEO | Sell | 3,000 | $15.04 | $45.1K | 338,575 |
| May 20, 2024 | Sethuraman Natarajan | Chief Scientific Officer | Sell | 18,980 | $15.16 | $287.7K | 208,032 |
| May 16, 2024 | KIM PETER S | Director | Buy | 25,000 | $14.59 | $364.7K | 92,412+37% |
| May 10, 2024 | KIM PETER S | Director | Buy | 4,476 | $14.14 | $63.3K | 67,412 |
| Apr 10, 2024 | KIM PETER S | Director | Buy | 2,600 | $13.57 | $35.3K | 62,936 |
| Apr 1, 2024 | KIM PETER S | Director | Buy | 1,512 | $13.75 | $20.8K | 60,336 |
| Mar 26, 2024 | KIM PETER S | Director | Buy | 9,048 | $13.58 | $122.9K | 58,824 |
| Mar 21, 2024 | KIM PETER S | Director | Buy | 2,732 | $12.81 | $35.0K | 49,776 |
| Mar 8, 2024 | Dowden Nathan J | President & COO | Sell | 1,826 | $12.32 | $22.5K | 137,204 |
| Mar 8, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 4,086 | $12.31 | $50.3K | 74,170 |
| Feb 20, 2024 | Doshi Dipal | CEO | Sell | 1,000 | $15.00 | $15.0K | 243,279 |
| Jan 18, 2024 | Doshi Dipal | CEO | Sell | 1,000 | $15.99 | $16.0K | 244,279 |
| Dec 26, 2023 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 12,500 | $15.59 | $194.8K | 53,248 |
Showing 1–50 of 111
1 / 3
TRDA Insider Buying Activity
The following table shows recent insider purchases of Entrada Therapeutics, Inc. (TRDA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | Zeiher Bernhardt G | director | Buy | 5,000 | $5.86 | $29.3K | 5,000 |
| Jun 26, 2024 | BAKER BROS. ADVISORS LP | Buy | 3,367,003 | $14.85 | $50.00M8.8% OS | 3,081,303 | |
| May 16, 2024 | KIM PETER S | Director | Buy | 25,000 | $14.59 | $364.7K | 92,412+37% |
| May 10, 2024 | KIM PETER S | Director | Buy | 4,476 | $14.14 | $63.3K | 67,412 |
| Apr 10, 2024 | KIM PETER S | Director | Buy | 2,600 | $13.57 | $35.3K | 62,936 |
| Apr 1, 2024 | KIM PETER S | Director | Buy | 1,512 | $13.75 | $20.8K | 60,336 |
| Mar 26, 2024 | KIM PETER S | Director | Buy | 9,048 | $13.58 | $122.9K | 58,824 |
| Mar 21, 2024 | KIM PETER S | Director | Buy | 2,732 | $12.81 | $35.0K | 49,776 |
TRDA Insider Selling Activity
The following table shows recent insider sales of Entrada Therapeutics, Inc. (TRDA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 4, 2026 | Sethuraman Natarajan | officer: President, Research & Develop. | Sell | 25,907 | $15.39 | $398.8K | 216,317 |
| May 4, 2026 | Dowden Nathan J | officer: President & COO | Sell | 15,000 | $15.33 | $230.0K | 198,588 |
| Apr 2, 2026 | WENTWORTH KORY JAMES | officer: Chief Financial Officer | Sell | 2,500 | $12.95 | $32.4K | 119,010 |
| Mar 11, 2026 | Dowden Nathan J | officer: President & COO | Sell | 15,010 | $13.04 | $195.8K | 210,482 |
| Mar 11, 2026 | WENTWORTH KORY JAMES | officer: Chief Financial Officer | Sell | 16,477 | $13.01 | $214.4K | 132,898 |
| Mar 6, 2026 | WENTWORTH KORY JAMES | officer: Chief Financial Officer | Sell | 7,988 | $12.25 | $97.9K | 137,987 |
| Nov 21, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 8,910 | $9.98 | $88.9K | 0 |
| Nov 14, 2025 | PARMAR KUSH | Director | Sell | 200,000 | $8.80 | $1.76M0.5% OS | 0 |
| Sep 2, 2025 | Doshi Dipal | CEO | Sell | 8,723 | $5.43 | $47.4K | 0 |
| Sep 2, 2025 | Dowden Nathan J | President & COO | Sell | 1,746 | $5.43 | $9.5K | 0 |
| Sep 2, 2025 | Sethuraman Natarajan | President, Research & Develop. | Sell | 1,760 | $5.43 | $9.6K | 0 |
| Sep 2, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 1,734 | $5.43 | $9.4K | 0 |
| Jul 9, 2025 | PARMAR KUSH | Director | Sell | 27,000 | $7.50 | $202.6K | 0 |
| Jun 27, 2025 | PARMAR KUSH | Director | Sell | 125,000 | $6.93 | $866.6K | 0 |
| Mar 17, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 1,784 | $10.67 | $19.0K | 0 |
| Mar 1, 2025 | Doshi Dipal | CEO | Sell | 17,566 | $11.68 | $205.1K | 0 |
| Mar 1, 2025 | Dowden Nathan J | President & COO | Sell | 5,144 | $11.68 | $60.1K | 0 |
| Mar 1, 2025 | Sethuraman Natarajan | President, Research & Develop. | Sell | 6,138 | $11.68 | $71.7K | 0 |
| Mar 1, 2025 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 4,929 | $11.68 | $57.6K | 0 |
| Dec 12, 2024 | MPM BIOVENTURES 2018, L.P. | Sell | 44,722 | $20.51 | $917.1K | 4,402,849 | |
| Dec 3, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 15,891 | $20.18 | $320.6K | 160,788 |
| Dec 3, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 6,000 | $19.99 | $119.9K | 73,849 |
| Nov 13, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 4,109 | $20.03 | $82.3K | 163,588 |
| Nov 13, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 8,637 | $19.98 | $172.6K | 73,849 |
| Nov 6, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 18,219 | $18.62 | $339.3K | 182,467 |
| Oct 18, 2024 | Sethuraman Natarajan | President, Research & Develop. | Sell | 600 | $18.00 | $10.8K | 183,216 |
| Sep 30, 2024 | Dowden Nathan J | President & COO | Sell | 847 | $16.00 | $13.6K | 125,149 |
| Sep 10, 2024 | Dowden Nathan J | President & COO | Sell | 2,303 | $15.09 | $34.8K | 127,900 |
| Sep 10, 2024 | Sethuraman Natarajan | Chief Scientific Officer | Sell | 3,242 | $15.12 | $49.0K | 186,458 |
| Sep 10, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 3,195 | $14.97 | $47.8K | 76,486 |
| Aug 20, 2024 | Dowden Nathan J | President & COO | Sell | 27,097 | $16.27 | $440.8K | 130,609 |
| Jul 16, 2024 | Doshi Dipal | CEO | Sell | 1,900 | $17.84 | $33.9K | 336,075 |
| Jul 16, 2024 | Sethuraman Natarajan | Chief Scientific Officer | Sell | 1,238 | $18.00 | $22.3K | 189,452 |
| Jul 10, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 1,758 | $14.95 | $26.3K | 81,412 |
| Jun 14, 2024 | Doshi Dipal | CEO | Sell | 1,000 | $16.17 | $16.2K | 336,375 |
| May 20, 2024 | Doshi Dipal | CEO | Sell | 3,000 | $15.04 | $45.1K | 338,575 |
| May 20, 2024 | Sethuraman Natarajan | Chief Scientific Officer | Sell | 18,980 | $15.16 | $287.7K | 208,032 |
| Mar 8, 2024 | Dowden Nathan J | President & COO | Sell | 1,826 | $12.32 | $22.5K | 137,204 |
| Mar 8, 2024 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 4,086 | $12.31 | $50.3K | 74,170 |
| Feb 20, 2024 | Doshi Dipal | CEO | Sell | 1,000 | $15.00 | $15.0K | 243,279 |
| Jan 18, 2024 | Doshi Dipal | CEO | Sell | 1,000 | $15.99 | $16.0K | 244,279 |
| Dec 26, 2023 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 12,500 | $15.59 | $194.8K | 53,248 |
TRDA Insiders
Similar Stocks to TRDA
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B